IntegrateRNA Launches Custom Aminoacyl-tRNA Synthesis Service to Advance Protein Engineering

IntegrateRNA, the R&D focused business division of Creative Biogene, has launched its Aminoacyl-tRNA In Vitro Synthesis Service, providing researchers with tools to generate customized aminoacylated tRNAs for advanced protein synthesis applications. This service supports the creation of non-canonical amino acid-containing proteins, which could transform protein engineering and therapeutic development.

The technology utilizes a robust in vitro translation system to covalently link amino acids to transfer RNA molecules through an enzyme-based process that mimics natural cellular translation. This approach enables high-yield production of aminoacylated tRNAs and supports the inclusion of non-canonical or modified amino acids, expanding the design possibilities for researchers. Scientists can now design custom proteins with enhanced stability, activity, or specificity, with potential applications in developing new therapeutics and industrial enzymes.

Marcia Brady, Head of Technology at Creative Biogene, emphasized the significance of this development, stating that synthesizing proteins with non-canonical amino acids represents a transformative advancement. This technology opens new possibilities for designing proteins with specific properties and could significantly accelerate biotechnology development timelines.

The service is anticipated to find applications across pharmaceutical R&D, protein engineering, and novel biologics development. Researchers can insert non-standard amino acids into proteins, creating variants with unique properties that may not be achievable through natural processes alone. This capability is particularly valuable for synthetic biology, drug discovery, and enzyme engineering applications.

Future plans for the platform include supporting an even broader array of amino acid modifications and scaling production to industrial levels. These advancements could have major impacts on synthetic biology and therapeutic protein development, potentially leading to next-generation biopharmaceuticals and engineered enzymes. The service represents a significant step forward in enabling more accurate and scalable protein synthesis for research and development purposes.